title: Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.
abstract: Visceral hyperalgesia has been suggested to play a role in the development of symptoms presented by irritable bowel syndrome patients. Otilonium bromide was developed to block smooth muscle Ca release to control cramping pain of these patients.
  
  
  OBJECTIVE
  to determine whether otilonium bromide can influence sensory thresholds of patients suffering from irritable bowel syndrome.
  
  
  METHODS
  15 patients with Rome-II positive IBS were tested by Synectics Visceral Stimulator Barostat using rapid phasic distension (870 ml/min). The sensory threshold for first sensation, stool, pain and maximum tolerable volume and pressure were measured. All of the parameters were tested before and 1 week after the initiation of otilonium bromide (Spasmomen, Berlin Chemie, 3x40 mg) therapy.
  
  
  RESULTS
  The perceptual thresholds for first sensation, stool, pain and maximum tolerable distention were, 8.8+/-1.7 Hgmm, 19.2+/-2.1 Hgmm, 26.3+/-2.8 Hgmm, 28.7+/-2.8 Hgmm for pressure, 90+/-21 ml, 145+/-28 ml, 208+/-25 ml, 213+/-28 ml for volume, before treatment, respectively. Otilonium bromide treatment did not influence the thresholds for first sensation and stool, 7.4+/-1.4 Hgmm, 20.7+/-4.6 Hgmm and 83+/-21 ml, 178+/-35.8 ml, respectively. The pressure threshold of pain was significantly higher 1 week after treatment (26.3+/-2.8 Hgmm vs. 29.1+/-5.5 Hgmm, P<0.05), but the volume threshold of this sensation remained unchanged (208+/-25 ml vs. 234+/-39 ml, not significant). The pressure (28.7+/-2.8 Hgmm vs. 38.1+/-3.4 Hgmm, P<0.05) and volume (213+/-28 ml vs. 278+/-27 ml, P<0.05) thresholds for maximum tolerable volume were increased by 7 days otilonium bromide treatment.
  
  
  CONCLUSIONS
  These data suggest that otilonium bromide enhances sensory thresholds to recto-sigmoideal distention.
authors.affiliation: First Department of Medicine, University of Pécs, H-7643 Pécs, Ifjúság u. 13, Hungary. akiraly@clinics.pote.hu
authors.forename: J
authors.initials: J
authors.lastname: Czimmer
authors.forename: G
authors.initials: G
authors.lastname: Süto
authors.forename: A
authors.initials: A
authors.lastname: Király
authors.forename: G
authors.initials: G
authors.lastname: Mózsik
mesh_terms: D000328:Adult; D002404:Catheterization; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011312:Pressure; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D012684:Sensory Thresholds / Q000187:drug effects*
chemical_list: D005765:Gastrointestinal Agents; D000644:Quaternary Ammonium Compounds; C013934:octylonium